Drug Description in Trials / DrugBank / KEGG DRUG
Search results
No. | 薬物名(臨床試験情報から抽出) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 |
---|---|---|---|---|---|---|
1 | ALL patients IN THE study will BE treated with ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
2 | Continued ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
3 | EU-ocrevus | - | - | - | - | 1件: 13 13 💬
|
4 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
5 | Natalizumab/natalizumab-sztn, alemtuzumab, ocrelizumab, rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, cladribine, ofatumumab, ublituximab-xiiy, ocrelizumab and hyaluronidase-ocsq (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬
| 1件: ITGA4 ITGA4 💬
| 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬
|
6 | Observation OF ocrelizumab AS treatment IN rrms patients (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
7 | Ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 4件: 11 11, 13, 46, 49 💬
|
8 | Ocrelizumab / rhumab 2h7 (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬
|
9 | Ocrelizumab 300 MG (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
10 | Ocrelizumab 300MG (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
11 | Ocrelizumab 300MG/10 ML (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
12 | Ocrelizumab 300MG/10ML (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
13 | Ocrelizumab 500MG (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬
|
14 | Ocrelizumab 600 MG (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
15 | Ocrelizumab AT home (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
16 | Ocrelizumab dose 1 (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
17 | Ocrelizumab dose 2 and dose 3 (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
18 | Ocrelizumab IV (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
19 | Ocrelizumab SC (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
20 | Ocrevus | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
21 | Ocrevus 300 MG, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
(Ocrevus, OCREVUS, OCREVUS ZUNOVO) 💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬
|
22 | Ocrevus-EU | - | - | - | - | 1件: 13 13 💬
|
23 | Ocrevus-US | - | - | - | - | 1件: 13 13 💬
|
24 | Perfusion OF treatment ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
25 | Short-course ocrelizumab (Ocrevus, OCREVUS, OCREVUS ZUNOVO) | - | - | - | - | 1件: 13 13 💬
|
26 | US-ocrevus | - | - | - | - | 1件: 13 13 💬
|